Search

Displaying results 2941 - 2950 of 5419 in total
  1. Drug

    AME-527

    go.drugbank.com/drugs/DB05879
    Experimental

    AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.

  2. Drug

    Penimepicycline

    go.drugbank.com/drugs/DB13264
    Experimental

    It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients [L2791].

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. … It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release.

  4. Drug

    Flunisolide

    go.drugbank.com/drugs/DB00180
    Approved

    Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoi...

    Categories: Corticosteroids for Systemic Use
  5. Drug

    Rofecoxib

    go.drugbank.com/drugs/DB00533
    ApprovedWithdrawn

    On September 30, 2004, Merck voluntarily withdrew rofecoxib from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use.

  6. Drug

    Crisaborole

    go.drugbank.com/drugs/DB05219
    ApprovedInvestigational

    Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.

  7. Drug

    AM336

    go.drugbank.com/drugs/DB06563
    Experimental

    Leconotide (development codes CNSB004 and AM336) is an omega-conotoxin peptide known for its analgesic properties, which work by blocking neuronal voltage-sensitive calcium channels.

  8. Drug

    8-chlorotheophylline

    go.drugbank.com/drugs/DB14132
    Experimental

    Its main use is in combination with [Diphenhydramine] as the antiemetic drug [Dimenhydrinate]. … The stimulant properties of 8-chlorotheophylline are thought to ward off the drowsiness caused by diphenhydramine's anti-histamine activity in the central nervous system. 8-chlorotheophylline produces

  9. Drug

    Uridine triacetate

    go.drugbank.com/drugs/DB09144
    Approved

    By pre-administering with uridine (as the prodrug uridine triacetate), higher doses of 5-FU can be given allowing for improved efficacy and a reduction in toxic side effects [A18578]. … When intracellular uridine nucleotides are restored into the normal range, overproduction of orotic acid is reduced by feedback inhibition, so that urinary excretion of orotic acid is also reduced.

  10. Drug

    Oxybutynin

    go.drugbank.com/drugs/DB01062
    ApprovedInvestigational

    [A183782,L8648] This drug relieves undesirable urinary symptoms, increasing the quality of life for patients affected by OAB. It is often used as first-line therapy for OAB.[A185990]